{"gene":"IL24","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":2003,"finding":"MDA-7/IL-24 protein binds to IL-20R1/IL-20R2 and IL-22R1/IL-20R2 receptor complexes on the cell surface, activating JAK/STAT signaling pathways (STAT1 and STAT3); however, cancer-specific apoptosis induction occurs through JAK/STAT-independent pathways, as JAK inhibitors (AG490), tyrosine kinase inhibitors, and STAT/JAK-deficient cells do not abrogate Ad.mda-7-induced apoptosis, whereas p38 MAPK inhibitor (SB203580) partially blocks killing.","method":"Pharmacological inhibitors of JAK/STAT pathway, STAT/JAK-deficient cell lines, receptor expression analysis, apoptosis assays","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitor approaches and genetic (STAT/JAK-deficient) cell lines, replicated across diverse cell lines","pmids":["12811827"],"is_preprint":false},{"year":2003,"finding":"Secreted MDA-7/IL-24 inhibits angiogenesis (endothelial cell differentiation and migration induced by VEGF and bFGF) through the IL-22 receptor; blocking antibody to IL-22 receptor abrogates this antiangiogenic activity in vitro and reduces tumor vascularization in vivo.","method":"In vitro endothelial differentiation/migration assays, blocking antibody, in vivo Matrigel plug assay, xenograft model with stable sMDA-7/IL-24-expressing cells","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — receptor blocking antibody plus multiple in vitro and in vivo assays in single study","pmids":["12941841"],"is_preprint":false},{"year":2006,"finding":"MDA-7/IL-24 physically interacts with the ER chaperone BiP/GRP78 through its C and F helices (identified by deletion and mutational analysis), localizes to the endoplasmic reticulum, and activates p38 MAPK and GADD gene expression, culminating in cancer-selective apoptosis.","method":"Deletion analysis, rationally designed mutagenesis, co-immunoprecipitation/physical interaction assay, subcellular localization, downstream signaling measurement","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis mapping of interaction domain plus physical interaction and functional consequence in same study","pmids":["16912197"],"is_preprint":false},{"year":2005,"finding":"Ad.mda-7-induced apoptosis in human ovarian cancer cells involves activation of transcription factors c-Jun and ATF2, which stimulate transcription of FasL and Fas; subsequent activation of NF-κB, FADD, FAF1, and caspase-8 mediates cell death. Inhibition of Fas by siRNA or FasL by blocking antibody significantly reduces apoptosis.","method":"Promoter-reporter gene analysis, siRNA knockdown of Fas, FasL blocking antibody (NOK-1), western blot for pathway components","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — reporter assay, siRNA, and antibody blockade with multiple pathway components validated","pmids":["15833826"],"is_preprint":false},{"year":2008,"finding":"Secreted MDA-7/IL-24 protein induces autocrine upregulation of endogenous mda-7/IL-24 mRNA through posttranscriptional stabilization (not promoter activation), dependent on de novo protein synthesis; this autocrine loop sustains ER stress (BiP/GRP78, GRP94, GADD153, phospho-eIF2α) and ROS production, mediating cancer-specific bystander killing.","method":"Promoter activity assay (ruling out transcriptional activation), mRNA stability assay, protein synthesis inhibitor, ER stress marker measurement, ROS detection","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (promoter assay, mRNA stability, protein synthesis blockade, ER stress markers) in single study","pmids":["18599461"],"is_preprint":false},{"year":2010,"finding":"MDA-7/IL-24-induced ER stress in prostate cancer cells causes apoptosis through translational inhibition of the anti-apoptotic protein Mcl-1; forced Mcl-1 expression blocks mda-7/IL-24 lethality, while Mcl-1 knockdown/knockout sensitizes cells. Mcl-1 downregulation relieves its association with Bak, causing Bak oligomerization and cell death.","method":"Forced expression of Mcl-1, siRNA/gene knockout of Mcl-1, co-immunoprecipitation of Mcl-1 with Bak, cell death assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — gain and loss-of-function with co-IP showing Mcl-1/Bak dissociation as mechanistic link","pmids":["20501829"],"is_preprint":false},{"year":2010,"finding":"MDA-7/IL-24 induces cancer-specific apoptosis through a ceramide-mediated ER stress pathway: Ad.mda-7 selectively elevates ceramides (C16, C24, C24:1) in prostate cancer but not normal cells via de novo synthesis (serine palmitoyltransferase) and acid sphingomyelinase; ceramide activates PP2A leading to BCL-2 dephosphorylation; ceramide inhibition blocks ER stress markers (BiP/GRP78, GADD153, phospho-eIF2α).","method":"Ceramide mass spectrometry, pharmacological inhibitors (myriocin/ISP1, fumonisin B1), siRNA knockdown of ASMase, PP2A activity assay, ER stress marker measurement","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 1-2 — lipidomics, siRNA, pharmacological inhibitors, and ER stress markers provide convergent mechanistic evidence","pmids":["19937735"],"is_preprint":false},{"year":2010,"finding":"PERK (protein kinase R-like ER kinase) activation is required for MDA-7/IL-24-induced ceramide generation and subsequent Ca2+ elevation and ROS production in glioma cells; PERK inhibition blocks ceramide/dihydroceramide generation, and ROS mediate autophagy and cell death. Ceramide synthase 6 (CerS6) and thioredoxin (TRX) are key downstream regulators.","method":"PERK inhibition/knockout (PERK-/- cells), ceramide measurement, Ca2+ measurement, ROS measurement, autophagy assay, orthotopic tumor model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — genetic PERK-/- cells plus pharmacological inhibitors and multiple biochemical readouts with in vivo validation","pmids":["20103619"],"is_preprint":false},{"year":2003,"finding":"Ad.mda-7 (MDA-7/IL-24) radiosensitizes glioma cells through JNK1/2 activation; inhibition of JNK1/2 (but not p38) abolishes radiosensitization, while Ad.mda-7 enhances p38 and ERK1/2 activity in non-irradiated cells.","method":"Pharmacological kinase inhibitors, colony formation/MTT assays, cell cycle analysis, kinase activity measurement","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibitor panel identifying JNK as required pathway, single lab","pmids":["14508103"],"is_preprint":false},{"year":2004,"finding":"MDA-7/IL-24 inhibits lung cancer cell migration and invasion by downregulating PI3K/Akt, focal adhesion kinase (FAK), and matrix metalloproteinases MMP-2 and MMP-9.","method":"Adenoviral overexpression, migration/invasion assays (Boyden chamber), western blot for pathway proteins, in vivo experimental metastasis model","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 — functional migration assays with molecular readouts and in vivo validation, single lab","pmids":["15093181"],"is_preprint":false},{"year":2008,"finding":"GST-MDA-7 (recombinant MDA-7/IL-24 protein) induces PERK-dependent autophagy in glioma cells; PERK activation drives formation of LC3-positive autophagic vacuoles (suppressed by ATG5/Beclin-1 knockdown or HSP70/BiP overexpression) that is causal in triggering mitochondrial apoptosis through JNK1-3 and BAX.","method":"PERK-/- cells, ATG5/Beclin-1 siRNA, autophagy inhibitors (3-methyladenine), LC3 immunofluorescence, co-immunoprecipitation, cell death assays","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 — genetic PERK-/- cells, siRNA knockdowns, and pharmacological inhibitors with multiple mechanistic readouts","pmids":["18299661"],"is_preprint":false},{"year":2009,"finding":"In renal carcinoma cells, recombinant MDA-7/IL-24 (GST-MDA-7) induces ceramide-dependent clustering of CD95 (Fas) at the plasma membrane, association of CD95 with procaspase-8, and subsequent PERK-dependent ER stress; CD95 clustering is blocked by knockdown of acid sphingomyelinase or ceramide synthase-6, and PERK knockout abolishes JNK/p38 signaling and cell death.","method":"CD95 clustering assay, co-immunoprecipitation of CD95 with procaspase-8, caspase-8 inhibitor, siRNA knockdown of ASMase/CerS6/CD95, PERK dominant-negative and knockout, autophagy (LC3) assay","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple siRNA knockdowns, genetic dominant-negative PERK, co-IP, and lipid measurements converge on mechanism","pmids":["19417161"],"is_preprint":false},{"year":2013,"finding":"MDA-7/IL-24 induces expression of SARI (suppressor of AP-1, induced by IFN) in cancer cells through p38 MAPK phosphorylation leading to GADD gene transcription; SARI expression is necessary for mda-7/IL-24 antitumor effects, as SARI antisense abolishes killing. Secreted MDA-7/IL-24 binds IL-20R1/IL-20R2 or IL-22R/IL-20R2 receptors to activate p38 MAPK and induce SARI.","method":"Antisense inhibition of SARI, p38 MAPK inhibitor, receptor binding, western blot for SARI/GADD, recombinant His-MDA-7 protein treatment","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — antisense loss-of-function plus pharmacological inhibition and recombinant protein activation, multiple cancer cell types","pmids":["24282278"],"is_preprint":false},{"year":2012,"finding":"MDA-7/IL-24 interacts with the pro-autophagic protein Beclin-1 in leukemia cells (co-immunoprecipitation), and mda-7/IL-24-induced autophagy is mediated through the class III PI3K/Beclin-1 complex; this autophagy promotes cancer cell survival, and its inhibition (wortmannin) enhances mda-7/IL-24-induced cell death.","method":"Co-immunoprecipitation of MDA-7/IL-24 with Beclin-1, immunofluorescence, autophagy inhibitors (wortmannin), ATG5/Beclin-1 knockdown, xenograft model","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus pharmacological inhibition and functional rescue, single lab","pmids":["19730452"],"is_preprint":false},{"year":2012,"finding":"Clusterin (CLU) is identified as an MDA-7/IL-24-interacting protein in prostate cancer cells; MDA-7/IL-24 decreases soluble CLU (sCLU) and increases nuclear CLU (nCLU), with early sCLU increase creating a cytoprotective effect. In sCLU-overexpressing cancer cells, MDA-7/IL-24 converts sCLU to nCLU causing G2/M arrest and apoptosis.","method":"Co-immunoprecipitation identifying CLU as MDA-7/IL-24 binding partner, stable cell lines overexpressing sCLU, western blot for sCLU/nCLU, cell cycle analysis, xenograft model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 3 — single co-IP identifying interaction plus functional studies with stable cell lines","pmids":["21732348"],"is_preprint":false},{"year":2010,"finding":"p38 MAPK stabilizes IL-24 mRNA by acting on the 3' UTR; p38 MAPK inhibitor (SB202190) accelerates IL-24 mRNA decay, and a constitutively active MKK6 mutant (which selectively activates p38 MAPK) reduces mRNA degradation mediated by the IL-24 3' UTR in a reporter construct.","method":"mRNA stability assay, p38 MAPK inhibitor, constitutively active MKK6 overexpression, tet-off 3' UTR reporter construct","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — reporter construct dissecting 3' UTR function, pharmacological and genetic manipulation of p38 MAPK, convergent evidence","pmids":["20072629"],"is_preprint":false},{"year":2012,"finding":"miR-203 directly targets IL24 mRNA in keratinocytes, providing posttranscriptional repression; validated by miR-203 overexpression, inhibition, and mutagenesis of the target site in primary keratinocytes and cell lines.","method":"miRNA overexpression/inhibition, mutagenesis of miR-203 binding site in IL24 3' UTR, quantitative RT-PCR, primary keratinocyte experiments","journal":"Cytokine","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis of binding site plus gain/loss-of-function in primary cells","pmids":["22917968"],"is_preprint":false},{"year":2008,"finding":"MDA-7/IL-24 in melanoma cells induces secretion of endogenous IFN-β (class I IFN), which leads to upregulation of IRF-2 (competing with IRF-1), downregulation of iNOS, and activation of TRAIL and Fas-FasL apoptotic cascades.","method":"ELISA for IFN-β secretion, IRF-1/IRF-2 expression analysis, TRAIL/FasL measurement, apoptosis assays in melanoma cell lines","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, correlative mechanistic pathway with ELISA and expression analysis","pmids":["18511292"],"is_preprint":false},{"year":2002,"finding":"Adenovirus-expressed MDA-7/IL-24 selectively increases the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins in melanoma cells, causes G2/M cell cycle arrest, and leads to secretion of MDA-7 protein; normal melanocytes do not undergo apoptosis.","method":"Adenoviral gene transfer, western blot for BCL-2 family proteins, cell cycle analysis (flow cytometry), ELISA for secreted protein, normal vs. cancer cell comparison","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical readouts with normal/cancer selectivity demonstrated, foundational mechanistic paper","pmids":["11850799"],"is_preprint":false},{"year":2020,"finding":"IL-17A binding to its receptor on Th17 cells activates NF-κB, which induces IL-24 expression in an autocrine loop; IL-24 in turn represses the Th17 cytokine program (GM-CSF, IL-17F) and in vivo treatment with IL-24 ameliorates autoimmune uveitis (EAU), while IL-24 silencing in Th17 cells enhances disease.","method":"In vitro mechanistic studies of NF-κB activation and IL-24 induction, IL-24 silencing in Th17 cells, in vivo EAU model with IL-24 treatment/silencing, human Th17 cell validation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — in vitro signaling mechanistic studies, in vivo gain/loss-of-function, validated in both mouse and human Th17 cells","pmids":["32673565"],"is_preprint":false},{"year":2022,"finding":"In Th17 cells, IL-24 acts cell-intrinsically and independently of its cell-surface receptor to promote IL-10 secretion; IL-24 is recruited to the inner mitochondrial membrane where it interacts with NADH dehydrogenase subunit Grim19 (NDUFA13, complex I), and together Grim19 and IL-24 promote accumulation of STAT3 in the mitochondrial compartment, acting as a rheostat to blunt nuclear STAT3 activity and support robust IL-10 responses.","method":"Subcellular fractionation/localization of IL-24 to mitochondria, co-immunoprecipitation with Grim19, receptor-independent functional studies, mitochondrial STAT3 accumulation measurement, EAE model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP identifying novel intracellular binding partner, subcellular localization to mitochondria, receptor-independence established, functional in vivo validation","pmids":["35819408"],"is_preprint":false},{"year":2020,"finding":"IL-24 synergizes with IL-4 to promote M2 macrophage polarization by suppressing IL-4-induced expression of SOCS1 and SOCS3, thereby enhancing STAT6/PPARγ signaling; IL-24 deficiency attenuates TGF-β1 production and M2 macrophage infiltration in bleomycin-induced pulmonary fibrosis.","method":"IL-24 knockout mice, SOCS1/SOCS3 expression analysis, STAT6/PPARγ signaling measurement, M2 macrophage quantification, BLM-induced fibrosis model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout model with mechanistic signaling analysis (SOCS1/3, STAT6/PPARγ) and disease model validation","pmids":["33144678"],"is_preprint":false},{"year":2015,"finding":"IL-24 post-transcriptionally regulates CXCR4 mRNA by decreasing its half-life (>40%), thereby reducing CXCR4 protein and downstream signaling (pAKT, pmTOR, pPRAS40, HIF-1α), and inhibiting lung cancer cell migration and invasion; this is shown using doxycycline-inducible IL-24 expression, CXCR4 siRNA, and combination with CXCR4 antagonists.","method":"Doxycycline-inducible stable IL-24 expression, CXCR4 mRNA stability assay (half-life measurement), western blot for downstream targets, migration/invasion assays, CXCR4 siRNA, luciferase reporter","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — inducible expression system, mRNA half-life measurement, siRNA and pharmacological validation, multiple downstream targets confirmed","pmids":["25775124"],"is_preprint":false},{"year":2019,"finding":"MDA-7/IL-24 downregulates DICER (miRNA processing enzyme) in cancer cells but not normal cells, through canonical IL-20/IL-22 receptors; downregulation is ROS-dependent and mediated through the melanogenesis-associated transcription factor MITF. DICER downregulation reduces mature miR-221 (without affecting pri-miR-221) and contributes to cancer cell death; DICER overexpression rescues cells from MDA-7/IL-24-induced death.","method":"Gain/loss-of-function for DICER, MITF, and receptor manipulation; ROS measurement; northern/qPCR for miRNA biogenesis intermediates; stable DICER-overexpressing cell lines; in vivo xenograft with stable DICER cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic gain/loss-of-function experiments, receptor dependence established, ROS mechanistic link, in vivo validation","pmids":["30842276"],"is_preprint":false},{"year":2011,"finding":"Pharmacological inhibition of Mcl-1 with Sabutoclax (BI-97C1) sensitizes prostate cancer cells to MDA-7/IL-24-induced apoptosis; the combination causes autophagy that facilitates NOXA- and Bim-induced, Bak/Bax-mediated mitochondrial apoptosis; ABT-737 (which does not inhibit Mcl-1) does not sensitize cells, confirming Mcl-1 specificity.","method":"Pharmacological Mcl-1 inhibition, autophagy assay, NOXA/Bim/Bak/Bax assessment, xenograft and transgenic mouse models (Hi-myc), TUNEL/Ki-67 staining","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — specific Mcl-1 inhibitor vs. negative control (ABT-737), multiple in vivo models, apoptosis pathway dissection","pmids":["21555592"],"is_preprint":false},{"year":2017,"finding":"ZBTB7A transcriptionally represses LINC00473 by directly binding its promoter; LINC00473 interacts with transcription factor C/EBPβ, facilitating C/EBPβ binding to the IL24 promoter and promoting IL24 transcription. Loss of ZBTB7A reduces IL24 expression and increases cisplatin resistance in osteosarcoma.","method":"ChIP assay (ZBTB7A binding to LINC00473 promoter), RNA-protein interaction (LINC00473-C/EBPβ), C/EBPβ ChIP at IL24 promoter, loss/gain-of-function experiments","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP data for transcriptional regulation and RNA-protein interaction identifying the pathway, single lab","pmids":["28942243"],"is_preprint":false},{"year":2010,"finding":"IL-24 inhibits TGFα-induced proliferation and migration of normal human epidermal keratinocytes (NHEKs) in vitro; IL-24 is expressed in keratinocytes during wound repair with maximum expression at days 2-6 post-wounding, induced by TGFα, TGFβ, IFNγ, and IFNβ.","method":"Immunohistochemistry of wound tissues, in vitro wound repair assay, migration assay, cytokine stimulation, western blot","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional migration/proliferation assays with cytokine induction data, single lab","pmids":["20545760"],"is_preprint":false},{"year":2013,"finding":"IL-24 produced by mast cells (induced by T cell-derived microvesicles) activates keratinocyte STAT3 phosphorylation in vitro, establishing a functional signaling link between MC-derived IL-24 and keratinocyte activation.","method":"Co-culture of mast cells with microvesicles, ELISA for IL-24 protein, STAT3 phosphorylation assay in keratinocytes treated with MC-conditioned medium, immunohistochemistry of psoriatic lesions","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 3 — in vitro functional assay (STAT3 phosphorylation) with conditioned medium approach, single lab","pmids":["23768573"],"is_preprint":false},{"year":2008,"finding":"IL-24 induces apoptosis of IL-2-activated (cycling) CLL B cells through dephosphorylation of STAT3 (via activation of tyrosine phosphatase PTP1B) and concomitant stabilization and phosphorylation of p53; blocking phospho-STAT3 (a transcriptional repressor of p53) relieves repression of p53, which then drives apoptosis via caspase pathway.","method":"Sequential cytokine treatment (IL-2 then IL-24), phospho-STAT3 western blot, pervanadate (phosphatase inhibitor) reversal, p53 transcription/protein/phosphorylation assay, pifithrin-α (p53 inhibitor) rescue, caspase inhibitor rescue","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological rescue with multiple inhibitors and STAT3/p53 mechanistic pathway validated, single lab","pmids":["18941194"],"is_preprint":false},{"year":2006,"finding":"IL-19, IL-20, and IL-24 signal through two heterodimeric receptor complexes: IL-20R1/IL-20R2 and IL-22R1/IL-20R2; both complexes are expressed on keratinocytes (IL-22R1 at 10-fold higher levels than IL-20R1), while immune cells lack these receptor chains and do not activate STAT molecules in response to these cytokines. IFN-γ further increases IL-22R1 and decreases IL-20R1 expression on keratinocytes.","method":"Quantitative receptor expression analysis (qPCR), STAT activation assay in immune cells and keratinocytes, cytokine stimulation experiments","journal":"Experimental dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic receptor expression and STAT activation analysis across multiple cell types, single lab","pmids":["17083366"],"is_preprint":false},{"year":2001,"finding":"The mouse ortholog of IL-24 (FISP, IL-4-induced secreted protein) is selectively expressed and secreted by Th2 cells; its expression requires two signals: TCR signaling involving protein kinase C activation and STAT6-dependent IL-4R signaling.","method":"Th1/Th2 differentiation assays, pharmacological inhibition of PKC, IL-4R blocking, STAT6 requirement analysis, protein secretion assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — defined dual signaling requirement for expression with pharmacological dissection, foundational for Th2 biology of IL-24 ortholog","pmids":["11342597"],"is_preprint":false},{"year":2020,"finding":"IL-24 promotes epithelial-mesenchymal transition (EMT) in bronchial epithelial cells via STAT3 and ERK1/2 signaling pathways (upregulating vimentin and α-SMA, downregulating E-cadherin); IL-37 reverses IL-24-induced EMT by blocking ERK1/2 and STAT3, and in vivo IL-24 silencing or IL-37 treatment reverses EMT biomarker expression in an HDM-induced asthma model.","method":"BEAS-2B cell stimulation with IL-24, EMT biomarker (E-cadherin, vimentin, α-SMA) assay, wound healing/Transwell migration, STAT3/ERK1/2 phosphorylation assay, siRNA-IL-24 in vivo in murine asthma model","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro signaling pathway identification plus in vivo siRNA validation, single lab","pmids":["36100847"],"is_preprint":false}],"current_model":"IL-24 (MDA-7/IL-24) is a secreted IL-10-family cytokine that signals canonically through IL-20R1/IL-20R2 and IL-22R1/IL-20R2 heterodimeric receptors to activate JAK/STAT pathways in epithelial/stromal target cells, but in cancer cells induces receptor-dependent or intracellular ER stress (through BiP/GRP78 interaction, PERK activation, ceramide generation via de novo and sphingomyelinase pathways, and ROS production) leading to translational suppression of Mcl-1, Bak oligomerization, p38 MAPK-driven GADD/SARI induction, and cancer-selective apoptosis or toxic autophagy; additionally, secreted MDA-7/IL-24 exerts antiangiogenic effects via the IL-22 receptor, drives an autocrine mRNA stabilization loop via p38 MAPK-mediated 3' UTR stabilization, downregulates DICER through an ROS/MITF axis, and in Th17 cells acts non-canonically by localizing to the inner mitochondrial membrane where it interacts with Grim19/NDUFA13 to promote mitochondrial STAT3 accumulation and IL-10 production, limiting immunopathology."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing that the mouse IL-24 ortholog (FISP) is a Th2-selective secreted cytokine requiring dual TCR/PKC and STAT6/IL-4R signals resolved the immune-cell context of IL-24 expression before its receptor biology was known.","evidence":"Th1/Th2 differentiation with pharmacological dissection of PKC and STAT6 requirements in mouse T cells","pmids":["11342597"],"confidence":"Medium","gaps":["Single lab; not replicated with genetic knockouts of PKC isoforms","Th2-selectivity was mouse-specific and later complicated by Th17 expression in humans"]},{"year":2002,"claim":"Demonstrating that adenoviral MDA-7/IL-24 selectively shifts the BAX/BCL-2 ratio and induces G2/M arrest in melanoma but not normal melanocytes established the cancer-selective killing paradigm that dominated subsequent mechanistic dissection.","evidence":"Adenoviral expression in paired normal/cancer melanocyte lines with BCL-2 family protein and cell-cycle analysis","pmids":["11850799"],"confidence":"Medium","gaps":["Mechanism of cancer selectivity not identified","Overexpression system; endogenous IL-24 levels not assessed"]},{"year":2003,"claim":"Identifying IL-20R1/IL-20R2 and IL-22R1/IL-20R2 as IL-24 receptors that activate JAK/STAT, while showing cancer-cell killing is JAK/STAT-independent and partially p38 MAPK-dependent, bifurcated the field into canonical signaling versus intracellular death pathways.","evidence":"JAK inhibitors, STAT/JAK-deficient cell lines, p38 MAPK inhibitor, and receptor expression analysis across cancer lines","pmids":["12811827"],"confidence":"High","gaps":["Identity of the intracellular death trigger remained unknown","p38 MAPK inhibitor only partially blocked killing, indicating additional pathways"]},{"year":2003,"claim":"Secreted MDA-7/IL-24 was shown to inhibit VEGF- and bFGF-driven angiogenesis through the IL-22 receptor, establishing a paracrine antitumor mechanism distinct from direct cancer-cell killing.","evidence":"IL-22R blocking antibody, endothelial differentiation/migration assays, in vivo Matrigel plug and xenograft models","pmids":["12941841"],"confidence":"High","gaps":["Downstream endothelial signaling pathway not delineated","Contribution of antiangiogenesis versus direct killing to in vivo efficacy unclear"]},{"year":2005,"claim":"Mapping the death-receptor arm showed MDA-7/IL-24 activates c-Jun/ATF2 to transcriptionally induce FasL and Fas, engaging FADD/caspase-8-mediated extrinsic apoptosis in ovarian cancer cells.","evidence":"FasL promoter-reporter, Fas siRNA, FasL blocking antibody, caspase-8 pathway analysis","pmids":["15833826"],"confidence":"High","gaps":["Whether Fas/FasL arm operates in non-ovarian cancers was not tested","Upstream trigger linking MDA-7/IL-24 to c-Jun/ATF2 activation not identified"]},{"year":2006,"claim":"Identifying BiP/GRP78 as a direct MDA-7/IL-24 binding partner via its C and F helices, with consequent p38 MAPK activation and GADD induction, provided the first molecular explanation for the intracellular ER-stress death pathway.","evidence":"Deletion/point mutagenesis of MDA-7/IL-24, co-immunoprecipitation with BiP/GRP78, subcellular ER localization","pmids":["16912197"],"confidence":"High","gaps":["Structural basis of BiP interaction not resolved at atomic level","Whether BiP binding is necessary or sufficient for cancer selectivity not tested with BiP knockdown"]},{"year":2008,"claim":"The discovery that secreted MDA-7/IL-24 autocrine-induces its own mRNA through posttranscriptional stabilization (not transcription), sustaining ER stress and ROS, explained the bystander killing phenomenon in untransduced neighboring cancer cells.","evidence":"Promoter activity ruling out transcriptional activation, mRNA stability assays, protein synthesis inhibitor, ER stress and ROS markers","pmids":["18599461"],"confidence":"High","gaps":["RNA-binding protein mediating stabilization not identified","Whether autocrine loop operates through the same IL-20R/IL-22R receptors not established"]},{"year":2008,"claim":"PERK was established as a required upstream kinase for MDA-7/IL-24-induced autophagy in glioma, linking ER stress to LC3-positive autophagic vacuole formation and subsequent BAX/JNK-mediated mitochondrial apoptosis.","evidence":"PERK−/− cells, ATG5/Beclin-1 siRNA, autophagy inhibitor 3-MA, recombinant GST-MDA-7 treatment","pmids":["18299661"],"confidence":"High","gaps":["Whether PERK activation is direct or secondary to BiP sequestration not resolved","Cell-type generality of autophagy-to-apoptosis conversion unclear"]},{"year":2010,"claim":"Ceramide was identified as a critical second messenger: MDA-7/IL-24 elevates C16/C24/C24:1 ceramides selectively in cancer cells via de novo synthesis and acid sphingomyelinase, activating PP2A to dephosphorylate BCL-2, while PERK was placed upstream of ceramide generation and ROS production.","evidence":"Ceramide mass spectrometry, myriocin/fumonisin B1 inhibitors, ASMase siRNA, PERK−/− cells, Ca²⁺ and ROS measurement","pmids":["19937735","20103619"],"confidence":"High","gaps":["Whether ceramide elevation is the primary cancer-selectivity determinant or a downstream amplifier is unclear","Role of specific ceramide synthases beyond CerS6 not fully explored"]},{"year":2010,"claim":"Translational suppression of Mcl-1 was identified as the key effector of ER stress-mediated apoptosis: MDA-7/IL-24-induced ER stress inhibits Mcl-1 translation, releasing Bak for oligomerization and mitochondrial apoptosis.","evidence":"Forced Mcl-1 expression rescue, Mcl-1 siRNA/knockout sensitization, Mcl-1–Bak co-immunoprecipitation showing dissociation","pmids":["20501829"],"confidence":"High","gaps":["Whether Mcl-1 translational suppression is eIF2α-phosphorylation-dependent was inferred but not directly tested with eIF2α mutants"]},{"year":2010,"claim":"p38 MAPK was shown to stabilize IL-24 mRNA via its 3′ UTR, providing the molecular basis for the autocrine amplification loop and positioning p38 MAPK as both a downstream effector and a feed-forward stabilizer of IL-24 expression.","evidence":"Tet-off 3′ UTR reporter, p38 MAPK inhibitor SB202190, constitutively active MKK6","pmids":["20072629"],"confidence":"High","gaps":["The specific RNA-binding protein(s) that p38 MAPK regulates to stabilize IL-24 mRNA remain unidentified","Whether this loop operates in immune cells in addition to cancer cells is unknown"]},{"year":2009,"claim":"Ceramide-dependent CD95 (Fas) clustering at the plasma membrane was linked to MDA-7/IL-24 action in renal carcinoma, unifying the ceramide and death-receptor pathways: ASMase/CerS6-generated ceramide causes CD95 aggregation and procaspase-8 recruitment, upstream of PERK-dependent JNK/p38 signaling.","evidence":"CD95 clustering assay, ASMase/CerS6 siRNA, PERK dominant-negative and knockout, co-IP of CD95 with procaspase-8","pmids":["19417161"],"confidence":"High","gaps":["Whether CD95 clustering is a general feature across cancer types or renal-carcinoma-specific","Temporal ordering of ceramide versus PERK activation not fully resolved"]},{"year":2013,"claim":"SARI (suppressor of AP-1) was identified as a necessary downstream effector of MDA-7/IL-24's antitumor activity, induced through receptor-mediated p38 MAPK signaling, connecting the extracellular signaling arm to intracellular tumor suppression.","evidence":"SARI antisense abolishing MDA-7/IL-24 killing, p38 MAPK inhibitor, recombinant His-MDA-7 acting through IL-20R/IL-22R receptors","pmids":["24282278"],"confidence":"High","gaps":["SARI's direct transcriptional targets mediating apoptosis not defined","Whether SARI is required in all cancer types not tested"]},{"year":2015,"claim":"IL-24 was shown to post-transcriptionally destabilize CXCR4 mRNA, reducing its half-life by >40%, thereby suppressing AKT/mTOR/HIF-1α signaling and cancer cell migration — extending IL-24's anti-invasion mechanism beyond FAK/MMP suppression.","evidence":"Doxycycline-inducible IL-24, CXCR4 mRNA half-life measurement, CXCR4 siRNA, migration/invasion assays","pmids":["25775124"],"confidence":"High","gaps":["The RNA-destabilizing mechanism (e.g., specific RBP or miRNA involved) not identified","Whether CXCR4 mRNA destabilization occurs in non-lung cancer contexts unknown"]},{"year":2019,"claim":"MDA-7/IL-24 was found to downregulate DICER through receptor-dependent ROS production and MITF suppression, cancer-selectively impairing miRNA biogenesis (e.g., reducing mature miR-221); DICER overexpression rescued cancer cells, establishing a novel effector arm.","evidence":"DICER gain/loss-of-function, MITF manipulation, ROS measurement, northern blot for miRNA intermediates, in vivo xenograft rescue","pmids":["30842276"],"confidence":"High","gaps":["Which DICER-dependent miRNAs beyond miR-221 are functionally important not mapped","How MITF downregulation specifically targets DICER transcription not resolved"]},{"year":2020,"claim":"In Th17 cells, IL-17A-induced NF-κB was shown to drive autocrine IL-24 expression, which in turn represses the pathogenic Th17 program (GM-CSF, IL-17F) and ameliorates autoimmune uveitis, establishing IL-24 as an intrinsic negative-feedback cytokine in Th17 biology.","evidence":"NF-κB signaling dissection, IL-24 silencing in Th17 cells, in vivo EAU model with IL-24 treatment/silencing, human Th17 validation","pmids":["32673565"],"confidence":"High","gaps":["Whether IL-24 represses GM-CSF/IL-17F transcriptionally or post-transcriptionally not resolved","Receptor dependence versus intracellular action in Th17 regulation not distinguished in this study"]},{"year":2020,"claim":"IL-24 was shown to synergize with IL-4 to promote M2 macrophage polarization by suppressing SOCS1/SOCS3, enhancing STAT6/PPARγ, and IL-24 deficiency attenuated pulmonary fibrosis, revealing a pro-fibrotic immunomodulatory role distinct from its antitumor function.","evidence":"IL-24 knockout mice, SOCS1/3 and STAT6/PPARγ signaling analysis, bleomycin-induced fibrosis model","pmids":["33144678"],"confidence":"High","gaps":["Whether IL-24 acts directly on macrophages or indirectly through other cell types not fully resolved","Receptor complex mediating IL-24's effect on macrophages not identified"]},{"year":2022,"claim":"The discovery that IL-24 localizes to the inner mitochondrial membrane and interacts with NDUFA13/Grim19 to promote mitochondrial STAT3 accumulation — independently of its cell-surface receptors — established a non-canonical cell-intrinsic mechanism by which IL-24 supports IL-10 production in Th17 cells and limits autoimmune pathology.","evidence":"Subcellular fractionation, co-immunoprecipitation with Grim19, receptor-independent functional assays, mitochondrial STAT3 measurement, EAE model","pmids":["35819408"],"confidence":"High","gaps":["How IL-24 is imported into the inner mitochondrial membrane is unknown","Whether mitochondrial IL-24 function extends to other immune or non-immune cell types not tested","Structural basis of IL-24–Grim19 interaction not resolved"]},{"year":null,"claim":"The molecular basis of cancer selectivity — why intracellular MDA-7/IL-24 triggers ER stress and apoptosis in tumor cells but not normal cells — remains mechanistically unresolved despite extensive downstream pathway characterization.","evidence":"","pmids":[],"confidence":"High","gaps":["No cancer-cell-specific factor or threshold mechanism identified","How mitochondrial and ER-stress functions relate to each other in immune cells is unexplored","No structural model of IL-24 in complex with BiP, Grim19, or receptors exists"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,12,29]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[19,21,23]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2,4,6]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,4,18,30]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,3,5,6,7,10,11,18,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,12,19,21,28,31]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,20,21]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[7,10,13,24]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[15,16,22,23]}],"complexes":[],"partners":["HSPA5","NDUFA13","IL20RB","IL20RA","IL22RA1","BECN1","CLU"],"other_free_text":[]},"mechanistic_narrative":"IL-24 (MDA-7) is an IL-10-family cytokine with dual functionality: it acts as a canonical secreted ligand through IL-20R1/IL-20R2 and IL-22R1/IL-20R2 receptor complexes to activate JAK/STAT signaling in epithelial and stromal cells, and it drives cancer-selective apoptosis and toxic autophagy through receptor-independent intracellular mechanisms involving ER stress, ceramide generation, and ROS production [PMID:12811827, PMID:19937735, PMID:20103619]. In cancer cells, MDA-7/IL-24 binds the ER chaperone BiP/GRP78 and activates PERK, triggering ceramide elevation via de novo synthesis and acid sphingomyelinase, PP2A-mediated BCL-2 dephosphorylation, translational suppression of Mcl-1 with consequent Bak oligomerization, and p38 MAPK-dependent induction of GADD genes and SARI [PMID:16912197, PMID:20501829, PMID:24282278, PMID:19417161]. Secreted IL-24 sustains its own expression through a p38 MAPK-dependent autocrine mRNA stabilization loop acting on the 3′ UTR, inhibits angiogenesis via the IL-22 receptor, downregulates DICER through an ROS/MITF axis, and suppresses tumor cell migration by destabilizing CXCR4 mRNA and inhibiting PI3K/Akt/FAK signaling [PMID:18599461, PMID:20072629, PMID:12941841, PMID:30842276, PMID:25775124]. In Th17 cells, IL-24 functions non-canonically by localizing to the inner mitochondrial membrane where it interacts with NDUFA13 (Grim19) to promote mitochondrial STAT3 accumulation, blunting nuclear STAT3 activity and supporting IL-10 production to limit immunopathology [PMID:35819408, PMID:32673565]."},"prefetch_data":{"uniprot":{"accession":"Q13007","full_name":"Interleukin-24","aliases":["Melanoma differentiation-associated gene 7 protein","MDA-7","Suppression of tumorigenicity 16 protein"],"length_aa":206,"mass_kda":23.8,"function":"Multifunctional cytokine mainly produced by T-cells that plays a regulatory role in immune response, tissue homeostasis, host defense, and oncogenesis (PubMed:25168428, PubMed:27687232). Possesses antiviral functions and induces the type I interferon response during influenza infection (PubMed:27687232). Signals through two receptor complexes IL20RA/IL20RB or IL20RB/IL22RA1 (PubMed:11706020, PubMed:30111632). In turn, stimulates the JAK1-STAT3 and MAPK pathways and promotes the secretion of pro-inflammatory mediators including IL8 and MMP1 (PubMed:25168428). Intracellularly, maintains endoplasmic reticulum homeostasis by restricting the eIF2alpha-CHOP pathway-mediated stress signal (By similarity). In addition, acts as a quality control mechanism for the ubiquitin proteasome system by alerting the cell to proteasome dysfunction through activation of PKR/EIF2AK2 (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q13007/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL24","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL24","total_profiled":1310},"omim":[{"mim_id":"607900","title":"FERM DOMAIN-CONTAINING KINDLIN 1; FERMT1","url":"https://www.omim.org/entry/607900"},{"mim_id":"605621","title":"INTERLEUKIN 20 RECEPTOR, BETA; IL20RB","url":"https://www.omim.org/entry/605621"},{"mim_id":"605620","title":"INTERLEUKIN 20 RECEPTOR, ALPHA; IL20RA","url":"https://www.omim.org/entry/605620"},{"mim_id":"605457","title":"INTERLEUKIN 22 RECEPTOR, ALPHA-1; IL22RA1","url":"https://www.omim.org/entry/605457"},{"mim_id":"604136","title":"INTERLEUKIN 24; IL24","url":"https://www.omim.org/entry/604136"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":5.5},{"tissue":"urinary bladder","ntpm":13.5}],"url":"https://www.proteinatlas.org/search/IL24"},"hgnc":{"alias_symbol":["mda-7","IL10B","Mob-5","C49A","FISP","IL-24"],"prev_symbol":["ST16"]},"alphafold":{"accession":"Q13007","domains":[{"cath_id":"1.20.1250.10","chopping":"54-206","consensus_level":"high","plddt":93.5907,"start":54,"end":206}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13007","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13007-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13007-F1-predicted_aligned_error_v6.png","plddt_mean":83.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL24","jax_strain_url":"https://www.jax.org/strain/search?query=IL24"},"sequence":{"accession":"Q13007","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13007.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13007/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13007"}},"corpus_meta":[{"pmid":"18405958","id":"PMC_18405958","title":"The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29.","date":"2008","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18405958","citation_count":256,"is_preprint":false},{"pmid":"17083366","id":"PMC_17083366","title":"Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs.","date":"2006","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17083366","citation_count":204,"is_preprint":false},{"pmid":"11850799","id":"PMC_11850799","title":"The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11850799","citation_count":180,"is_preprint":false},{"pmid":"16287994","id":"PMC_16287994","title":"Is mda-7/IL-24 a \"magic bullet\" for cancer?","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16287994","citation_count":179,"is_preprint":false},{"pmid":"12941841","id":"PMC_12941841","title":"Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12941841","citation_count":163,"is_preprint":false},{"pmid":"16464504","id":"PMC_16464504","title":"mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.","date":"2006","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16464504","citation_count":160,"is_preprint":false},{"pmid":"32673565","id":"PMC_32673565","title":"The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24.","date":"2020","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/32673565","citation_count":149,"is_preprint":false},{"pmid":"14508078","id":"PMC_14508078","title":"mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic.","date":"2003","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/14508078","citation_count":145,"is_preprint":false},{"pmid":"12485618","id":"PMC_12485618","title":"MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12485618","citation_count":143,"is_preprint":false},{"pmid":"11844832","id":"PMC_11844832","title":"Loss of MDA-7 expression with progression of melanoma.","date":"2002","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11844832","citation_count":123,"is_preprint":false},{"pmid":"33144678","id":"PMC_33144678","title":"IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.","date":"2020","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/33144678","citation_count":121,"is_preprint":false},{"pmid":"18599461","id":"PMC_18599461","title":"Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18599461","citation_count":114,"is_preprint":false},{"pmid":"16912197","id":"PMC_16912197","title":"BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16912197","citation_count":112,"is_preprint":false},{"pmid":"16000066","id":"PMC_16000066","title":"Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.","date":"2005","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16000066","citation_count":109,"is_preprint":false},{"pmid":"21555592","id":"PMC_21555592","title":"Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21555592","citation_count":107,"is_preprint":false},{"pmid":"25001534","id":"PMC_25001534","title":"MDA-7/IL-24: multifunctional cancer killing cytokine.","date":"2014","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/25001534","citation_count":104,"is_preprint":false},{"pmid":"20926331","id":"PMC_20926331","title":"mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.","date":"2010","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20926331","citation_count":97,"is_preprint":false},{"pmid":"22917968","id":"PMC_22917968","title":"Regulation of pro-inflammatory cytokines TNFα and IL24 by microRNA-203 in primary keratinocytes.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22917968","citation_count":95,"is_preprint":false},{"pmid":"20103619","id":"PMC_20103619","title":"PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103619","citation_count":93,"is_preprint":false},{"pmid":"15194048","id":"PMC_15194048","title":"Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation.","date":"2004","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15194048","citation_count":88,"is_preprint":false},{"pmid":"15093181","id":"PMC_15093181","title":"Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells.","date":"2004","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15093181","citation_count":87,"is_preprint":false},{"pmid":"12811827","id":"PMC_12811827","title":"Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12811827","citation_count":86,"is_preprint":false},{"pmid":"14508103","id":"PMC_14508103","title":"mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling.","date":"2003","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/14508103","citation_count":86,"is_preprint":false},{"pmid":"31356866","id":"PMC_31356866","title":"Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.","date":"2019","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/31356866","citation_count":82,"is_preprint":false},{"pmid":"23768573","id":"PMC_23768573","title":"T cell-derived microvesicles induce mast cell production of IL-24: relevance to inflammatory skin diseases.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23768573","citation_count":77,"is_preprint":false},{"pmid":"15833826","id":"PMC_15833826","title":"Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15833826","citation_count":73,"is_preprint":false},{"pmid":"12941475","id":"PMC_12941475","title":"IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12941475","citation_count":72,"is_preprint":false},{"pmid":"17208263","id":"PMC_17208263","title":"Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.","date":"2006","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17208263","citation_count":72,"is_preprint":false},{"pmid":"11342597","id":"PMC_11342597","title":"Cutting edge: FISP (IL-4-induced secreted protein), a novel cytokine-like molecule secreted by Th2 cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11342597","citation_count":67,"is_preprint":false},{"pmid":"24527982","id":"PMC_24527982","title":"Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study.","date":"2014","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24527982","citation_count":67,"is_preprint":false},{"pmid":"20501829","id":"PMC_20501829","title":"Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20501829","citation_count":66,"is_preprint":false},{"pmid":"15580305","id":"PMC_15580305","title":"Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15580305","citation_count":65,"is_preprint":false},{"pmid":"12395925","id":"PMC_12395925","title":"mda-7 (IL-24): signaling and functional roles.","date":"2002","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/12395925","citation_count":61,"is_preprint":false},{"pmid":"25775124","id":"PMC_25775124","title":"IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25775124","citation_count":60,"is_preprint":false},{"pmid":"10381256","id":"PMC_10381256","title":"Cutaneous rat wounds express c49a, a novel gene with homology to the human melanoma differentiation associated gene, mda-7.","date":"1999","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10381256","citation_count":60,"is_preprint":false},{"pmid":"19937735","id":"PMC_19937735","title":"Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19937735","citation_count":59,"is_preprint":false},{"pmid":"18299661","id":"PMC_18299661","title":"PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells.","date":"2008","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/18299661","citation_count":52,"is_preprint":false},{"pmid":"17477796","id":"PMC_17477796","title":"Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy?","date":"2007","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17477796","citation_count":52,"is_preprint":false},{"pmid":"36100847","id":"PMC_36100847","title":"IL-37 protects against airway remodeling by reversing bronchial epithelial-mesenchymal transition via IL-24 signaling pathway in chronic asthma.","date":"2022","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/36100847","citation_count":52,"is_preprint":false},{"pmid":"18046450","id":"PMC_18046450","title":"Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18046450","citation_count":52,"is_preprint":false},{"pmid":"17263806","id":"PMC_17263806","title":"Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis.","date":"2007","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17263806","citation_count":51,"is_preprint":false},{"pmid":"20732354","id":"PMC_20732354","title":"The development of MDA-7/IL-24 as a cancer therapeutic.","date":"2010","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20732354","citation_count":50,"is_preprint":false},{"pmid":"21073280","id":"PMC_21073280","title":"IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.","date":"2010","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/21073280","citation_count":50,"is_preprint":false},{"pmid":"18774929","id":"PMC_18774929","title":"Ad-MDA-7; INGN 241: a review of preclinical and clinical experience.","date":"2008","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18774929","citation_count":49,"is_preprint":false},{"pmid":"18483274","id":"PMC_18483274","title":"Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18483274","citation_count":48,"is_preprint":false},{"pmid":"20545760","id":"PMC_20545760","title":"IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.","date":"2010","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20545760","citation_count":48,"is_preprint":false},{"pmid":"20150932","id":"PMC_20150932","title":"Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells.","date":"2010","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20150932","citation_count":47,"is_preprint":false},{"pmid":"29551126","id":"PMC_29551126","title":"Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.","date":"2018","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29551126","citation_count":46,"is_preprint":false},{"pmid":"24282278","id":"PMC_24282278","title":"Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24282278","citation_count":46,"is_preprint":false},{"pmid":"28942243","id":"PMC_28942243","title":"ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity.","date":"2017","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28942243","citation_count":44,"is_preprint":false},{"pmid":"27624484","id":"PMC_27624484","title":"Macrophages promote the growth and invasion of endometrial stromal cells by downregulating IL-24 in endometriosis.","date":"2016","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27624484","citation_count":44,"is_preprint":false},{"pmid":"12182458","id":"PMC_12182458","title":"IL-24 is expressed by rat and human macrophages.","date":"2002","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/12182458","citation_count":42,"is_preprint":false},{"pmid":"14633130","id":"PMC_14633130","title":"DNA oligonucleotide microarray technology identifies fisp-12 among other potential fibrogenic genes following murine unilateral ureteral obstruction (UUO): modulation during epithelial-mesenchymal transition.","date":"2003","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/14633130","citation_count":41,"is_preprint":false},{"pmid":"21780116","id":"PMC_21780116","title":"Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21780116","citation_count":41,"is_preprint":false},{"pmid":"20613485","id":"PMC_20613485","title":"MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.","date":"2010","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/20613485","citation_count":41,"is_preprint":false},{"pmid":"19417161","id":"PMC_19417161","title":"MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.","date":"2009","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19417161","citation_count":40,"is_preprint":false},{"pmid":"26474456","id":"PMC_26474456","title":"MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26474456","citation_count":40,"is_preprint":false},{"pmid":"17235306","id":"PMC_17235306","title":"mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.","date":"2007","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17235306","citation_count":40,"is_preprint":false},{"pmid":"16646087","id":"PMC_16646087","title":"Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16646087","citation_count":40,"is_preprint":false},{"pmid":"28781949","id":"PMC_28781949","title":"miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis.","date":"2017","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/28781949","citation_count":40,"is_preprint":false},{"pmid":"20735832","id":"PMC_20735832","title":"Tumour suppressor function of MDA-7/IL-24 in human breast cancer.","date":"2010","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/20735832","citation_count":39,"is_preprint":false},{"pmid":"20072629","id":"PMC_20072629","title":"The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20072629","citation_count":39,"is_preprint":false},{"pmid":"34616394","id":"PMC_34616394","title":"Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34616394","citation_count":38,"is_preprint":false},{"pmid":"18413837","id":"PMC_18413837","title":"Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18413837","citation_count":37,"is_preprint":false},{"pmid":"15713900","id":"PMC_15713900","title":"Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.","date":"2005","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15713900","citation_count":37,"is_preprint":false},{"pmid":"33321923","id":"PMC_33321923","title":"IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33321923","citation_count":37,"is_preprint":false},{"pmid":"19270721","id":"PMC_19270721","title":"Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24.","date":"2009","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/19270721","citation_count":36,"is_preprint":false},{"pmid":"28805796","id":"PMC_28805796","title":"Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo.","date":"2017","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28805796","citation_count":35,"is_preprint":false},{"pmid":"21732348","id":"PMC_21732348","title":"mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21732348","citation_count":33,"is_preprint":false},{"pmid":"17274815","id":"PMC_17274815","title":"MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17274815","citation_count":33,"is_preprint":false},{"pmid":"18941194","id":"PMC_18941194","title":"IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18941194","citation_count":32,"is_preprint":false},{"pmid":"16475947","id":"PMC_16475947","title":"MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic.","date":"2006","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16475947","citation_count":31,"is_preprint":false},{"pmid":"23481022","id":"PMC_23481022","title":"Stabilization of MDA-7/IL-24 for colon cancer therapy.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23481022","citation_count":31,"is_preprint":false},{"pmid":"19730452","id":"PMC_19730452","title":"Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo.","date":"2009","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19730452","citation_count":31,"is_preprint":false},{"pmid":"27208781","id":"PMC_27208781","title":"Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27208781","citation_count":29,"is_preprint":false},{"pmid":"27209087","id":"PMC_27209087","title":"Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27209087","citation_count":27,"is_preprint":false},{"pmid":"18505472","id":"PMC_18505472","title":"IL-24: a classic cytokine and/or a potential cure for cancer?","date":"2008","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18505472","citation_count":27,"is_preprint":false},{"pmid":"18511292","id":"PMC_18511292","title":"Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.","date":"2008","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18511292","citation_count":27,"is_preprint":false},{"pmid":"16225913","id":"PMC_16225913","title":"Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy.","date":"2005","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16225913","citation_count":26,"is_preprint":false},{"pmid":"20165905","id":"PMC_20165905","title":"Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.","date":"2010","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20165905","citation_count":26,"is_preprint":false},{"pmid":"28369789","id":"PMC_28369789","title":"Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.","date":"2017","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28369789","citation_count":26,"is_preprint":false},{"pmid":"32495855","id":"PMC_32495855","title":"MiRNA-203a-3p inhibits inflammatory response in preeclampsia through regulating IL24.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32495855","citation_count":25,"is_preprint":false},{"pmid":"16924242","id":"PMC_16924242","title":"Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16924242","citation_count":25,"is_preprint":false},{"pmid":"17069926","id":"PMC_17069926","title":"The murine liver is a potential target organ for IL-19, IL-20 and IL-24: Type I Interferons and LPS regulate the expression of IL-20R2.","date":"2006","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/17069926","citation_count":24,"is_preprint":false},{"pmid":"29934341","id":"PMC_29934341","title":"Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29934341","citation_count":24,"is_preprint":false},{"pmid":"32425553","id":"PMC_32425553","title":"An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32425553","citation_count":24,"is_preprint":false},{"pmid":"15120649","id":"PMC_15120649","title":"Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24.","date":"2004","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15120649","citation_count":24,"is_preprint":false},{"pmid":"18593364","id":"PMC_18593364","title":"Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis.","date":"2008","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/18593364","citation_count":23,"is_preprint":false},{"pmid":"30842276","id":"PMC_30842276","title":"MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30842276","citation_count":22,"is_preprint":false},{"pmid":"35819408","id":"PMC_35819408","title":"IL-24 intrinsically regulates Th17 cell pathogenicity in mice.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35819408","citation_count":22,"is_preprint":false},{"pmid":"23110359","id":"PMC_23110359","title":"Expression of IL-24 and IL-24 receptors in human wound tissues and the biological implications of IL-24 on keratinocytes.","date":"2012","source":"Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","url":"https://pubmed.ncbi.nlm.nih.gov/23110359","citation_count":22,"is_preprint":false},{"pmid":"38347092","id":"PMC_38347092","title":"IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells.","date":"2024","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38347092","citation_count":22,"is_preprint":false},{"pmid":"31462501","id":"PMC_31462501","title":"Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31462501","citation_count":21,"is_preprint":false},{"pmid":"16783343","id":"PMC_16783343","title":"Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.","date":"2006","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16783343","citation_count":21,"is_preprint":false},{"pmid":"22025528","id":"PMC_22025528","title":"AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22025528","citation_count":20,"is_preprint":false},{"pmid":"21282359","id":"PMC_21282359","title":"Novel functions for mda-7/IL-24 and IL-24 delE5: regulation of differentiation of acute myeloid leukemic cells.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21282359","citation_count":20,"is_preprint":false},{"pmid":"36174993","id":"PMC_36174993","title":"IL-24 Contributes to Neutrophilic Asthma in an IL-17A-Dependent Manner and Is Suppressed by IL-37.","date":"2022","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/36174993","citation_count":20,"is_preprint":false},{"pmid":"24025359","id":"PMC_24025359","title":"Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.","date":"2013","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24025359","citation_count":20,"is_preprint":false},{"pmid":"31972354","id":"PMC_31972354","title":"IL-24 inhibits endometrial cancer cell proliferation by promoting apoptosis through the mitochondrial intrinsic signaling pathway.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31972354","citation_count":20,"is_preprint":false},{"pmid":"16213894","id":"PMC_16213894","title":"Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.","date":"2005","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16213894","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53491,"output_tokens":8603,"usd":0.144759},"stage2":{"model":"claude-opus-4-6","input_tokens":12400,"output_tokens":4863,"usd":0.275363},"total_usd":0.420122,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"MDA-7/IL-24 protein binds to IL-20R1/IL-20R2 and IL-22R1/IL-20R2 receptor complexes on the cell surface, activating JAK/STAT signaling pathways (STAT1 and STAT3); however, cancer-specific apoptosis induction occurs through JAK/STAT-independent pathways, as JAK inhibitors (AG490), tyrosine kinase inhibitors, and STAT/JAK-deficient cells do not abrogate Ad.mda-7-induced apoptosis, whereas p38 MAPK inhibitor (SB203580) partially blocks killing.\",\n      \"method\": \"Pharmacological inhibitors of JAK/STAT pathway, STAT/JAK-deficient cell lines, receptor expression analysis, apoptosis assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitor approaches and genetic (STAT/JAK-deficient) cell lines, replicated across diverse cell lines\",\n      \"pmids\": [\"12811827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Secreted MDA-7/IL-24 inhibits angiogenesis (endothelial cell differentiation and migration induced by VEGF and bFGF) through the IL-22 receptor; blocking antibody to IL-22 receptor abrogates this antiangiogenic activity in vitro and reduces tumor vascularization in vivo.\",\n      \"method\": \"In vitro endothelial differentiation/migration assays, blocking antibody, in vivo Matrigel plug assay, xenograft model with stable sMDA-7/IL-24-expressing cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor blocking antibody plus multiple in vitro and in vivo assays in single study\",\n      \"pmids\": [\"12941841\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MDA-7/IL-24 physically interacts with the ER chaperone BiP/GRP78 through its C and F helices (identified by deletion and mutational analysis), localizes to the endoplasmic reticulum, and activates p38 MAPK and GADD gene expression, culminating in cancer-selective apoptosis.\",\n      \"method\": \"Deletion analysis, rationally designed mutagenesis, co-immunoprecipitation/physical interaction assay, subcellular localization, downstream signaling measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis mapping of interaction domain plus physical interaction and functional consequence in same study\",\n      \"pmids\": [\"16912197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ad.mda-7-induced apoptosis in human ovarian cancer cells involves activation of transcription factors c-Jun and ATF2, which stimulate transcription of FasL and Fas; subsequent activation of NF-κB, FADD, FAF1, and caspase-8 mediates cell death. Inhibition of Fas by siRNA or FasL by blocking antibody significantly reduces apoptosis.\",\n      \"method\": \"Promoter-reporter gene analysis, siRNA knockdown of Fas, FasL blocking antibody (NOK-1), western blot for pathway components\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay, siRNA, and antibody blockade with multiple pathway components validated\",\n      \"pmids\": [\"15833826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Secreted MDA-7/IL-24 protein induces autocrine upregulation of endogenous mda-7/IL-24 mRNA through posttranscriptional stabilization (not promoter activation), dependent on de novo protein synthesis; this autocrine loop sustains ER stress (BiP/GRP78, GRP94, GADD153, phospho-eIF2α) and ROS production, mediating cancer-specific bystander killing.\",\n      \"method\": \"Promoter activity assay (ruling out transcriptional activation), mRNA stability assay, protein synthesis inhibitor, ER stress marker measurement, ROS detection\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (promoter assay, mRNA stability, protein synthesis blockade, ER stress markers) in single study\",\n      \"pmids\": [\"18599461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MDA-7/IL-24-induced ER stress in prostate cancer cells causes apoptosis through translational inhibition of the anti-apoptotic protein Mcl-1; forced Mcl-1 expression blocks mda-7/IL-24 lethality, while Mcl-1 knockdown/knockout sensitizes cells. Mcl-1 downregulation relieves its association with Bak, causing Bak oligomerization and cell death.\",\n      \"method\": \"Forced expression of Mcl-1, siRNA/gene knockout of Mcl-1, co-immunoprecipitation of Mcl-1 with Bak, cell death assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain and loss-of-function with co-IP showing Mcl-1/Bak dissociation as mechanistic link\",\n      \"pmids\": [\"20501829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MDA-7/IL-24 induces cancer-specific apoptosis through a ceramide-mediated ER stress pathway: Ad.mda-7 selectively elevates ceramides (C16, C24, C24:1) in prostate cancer but not normal cells via de novo synthesis (serine palmitoyltransferase) and acid sphingomyelinase; ceramide activates PP2A leading to BCL-2 dephosphorylation; ceramide inhibition blocks ER stress markers (BiP/GRP78, GADD153, phospho-eIF2α).\",\n      \"method\": \"Ceramide mass spectrometry, pharmacological inhibitors (myriocin/ISP1, fumonisin B1), siRNA knockdown of ASMase, PP2A activity assay, ER stress marker measurement\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — lipidomics, siRNA, pharmacological inhibitors, and ER stress markers provide convergent mechanistic evidence\",\n      \"pmids\": [\"19937735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PERK (protein kinase R-like ER kinase) activation is required for MDA-7/IL-24-induced ceramide generation and subsequent Ca2+ elevation and ROS production in glioma cells; PERK inhibition blocks ceramide/dihydroceramide generation, and ROS mediate autophagy and cell death. Ceramide synthase 6 (CerS6) and thioredoxin (TRX) are key downstream regulators.\",\n      \"method\": \"PERK inhibition/knockout (PERK-/- cells), ceramide measurement, Ca2+ measurement, ROS measurement, autophagy assay, orthotopic tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic PERK-/- cells plus pharmacological inhibitors and multiple biochemical readouts with in vivo validation\",\n      \"pmids\": [\"20103619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ad.mda-7 (MDA-7/IL-24) radiosensitizes glioma cells through JNK1/2 activation; inhibition of JNK1/2 (but not p38) abolishes radiosensitization, while Ad.mda-7 enhances p38 and ERK1/2 activity in non-irradiated cells.\",\n      \"method\": \"Pharmacological kinase inhibitors, colony formation/MTT assays, cell cycle analysis, kinase activity measurement\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibitor panel identifying JNK as required pathway, single lab\",\n      \"pmids\": [\"14508103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MDA-7/IL-24 inhibits lung cancer cell migration and invasion by downregulating PI3K/Akt, focal adhesion kinase (FAK), and matrix metalloproteinases MMP-2 and MMP-9.\",\n      \"method\": \"Adenoviral overexpression, migration/invasion assays (Boyden chamber), western blot for pathway proteins, in vivo experimental metastasis model\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional migration assays with molecular readouts and in vivo validation, single lab\",\n      \"pmids\": [\"15093181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GST-MDA-7 (recombinant MDA-7/IL-24 protein) induces PERK-dependent autophagy in glioma cells; PERK activation drives formation of LC3-positive autophagic vacuoles (suppressed by ATG5/Beclin-1 knockdown or HSP70/BiP overexpression) that is causal in triggering mitochondrial apoptosis through JNK1-3 and BAX.\",\n      \"method\": \"PERK-/- cells, ATG5/Beclin-1 siRNA, autophagy inhibitors (3-methyladenine), LC3 immunofluorescence, co-immunoprecipitation, cell death assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic PERK-/- cells, siRNA knockdowns, and pharmacological inhibitors with multiple mechanistic readouts\",\n      \"pmids\": [\"18299661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In renal carcinoma cells, recombinant MDA-7/IL-24 (GST-MDA-7) induces ceramide-dependent clustering of CD95 (Fas) at the plasma membrane, association of CD95 with procaspase-8, and subsequent PERK-dependent ER stress; CD95 clustering is blocked by knockdown of acid sphingomyelinase or ceramide synthase-6, and PERK knockout abolishes JNK/p38 signaling and cell death.\",\n      \"method\": \"CD95 clustering assay, co-immunoprecipitation of CD95 with procaspase-8, caspase-8 inhibitor, siRNA knockdown of ASMase/CerS6/CD95, PERK dominant-negative and knockout, autophagy (LC3) assay\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple siRNA knockdowns, genetic dominant-negative PERK, co-IP, and lipid measurements converge on mechanism\",\n      \"pmids\": [\"19417161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MDA-7/IL-24 induces expression of SARI (suppressor of AP-1, induced by IFN) in cancer cells through p38 MAPK phosphorylation leading to GADD gene transcription; SARI expression is necessary for mda-7/IL-24 antitumor effects, as SARI antisense abolishes killing. Secreted MDA-7/IL-24 binds IL-20R1/IL-20R2 or IL-22R/IL-20R2 receptors to activate p38 MAPK and induce SARI.\",\n      \"method\": \"Antisense inhibition of SARI, p38 MAPK inhibitor, receptor binding, western blot for SARI/GADD, recombinant His-MDA-7 protein treatment\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antisense loss-of-function plus pharmacological inhibition and recombinant protein activation, multiple cancer cell types\",\n      \"pmids\": [\"24282278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MDA-7/IL-24 interacts with the pro-autophagic protein Beclin-1 in leukemia cells (co-immunoprecipitation), and mda-7/IL-24-induced autophagy is mediated through the class III PI3K/Beclin-1 complex; this autophagy promotes cancer cell survival, and its inhibition (wortmannin) enhances mda-7/IL-24-induced cell death.\",\n      \"method\": \"Co-immunoprecipitation of MDA-7/IL-24 with Beclin-1, immunofluorescence, autophagy inhibitors (wortmannin), ATG5/Beclin-1 knockdown, xenograft model\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus pharmacological inhibition and functional rescue, single lab\",\n      \"pmids\": [\"19730452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Clusterin (CLU) is identified as an MDA-7/IL-24-interacting protein in prostate cancer cells; MDA-7/IL-24 decreases soluble CLU (sCLU) and increases nuclear CLU (nCLU), with early sCLU increase creating a cytoprotective effect. In sCLU-overexpressing cancer cells, MDA-7/IL-24 converts sCLU to nCLU causing G2/M arrest and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation identifying CLU as MDA-7/IL-24 binding partner, stable cell lines overexpressing sCLU, western blot for sCLU/nCLU, cell cycle analysis, xenograft model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single co-IP identifying interaction plus functional studies with stable cell lines\",\n      \"pmids\": [\"21732348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p38 MAPK stabilizes IL-24 mRNA by acting on the 3' UTR; p38 MAPK inhibitor (SB202190) accelerates IL-24 mRNA decay, and a constitutively active MKK6 mutant (which selectively activates p38 MAPK) reduces mRNA degradation mediated by the IL-24 3' UTR in a reporter construct.\",\n      \"method\": \"mRNA stability assay, p38 MAPK inhibitor, constitutively active MKK6 overexpression, tet-off 3' UTR reporter construct\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reporter construct dissecting 3' UTR function, pharmacological and genetic manipulation of p38 MAPK, convergent evidence\",\n      \"pmids\": [\"20072629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-203 directly targets IL24 mRNA in keratinocytes, providing posttranscriptional repression; validated by miR-203 overexpression, inhibition, and mutagenesis of the target site in primary keratinocytes and cell lines.\",\n      \"method\": \"miRNA overexpression/inhibition, mutagenesis of miR-203 binding site in IL24 3' UTR, quantitative RT-PCR, primary keratinocyte experiments\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of binding site plus gain/loss-of-function in primary cells\",\n      \"pmids\": [\"22917968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MDA-7/IL-24 in melanoma cells induces secretion of endogenous IFN-β (class I IFN), which leads to upregulation of IRF-2 (competing with IRF-1), downregulation of iNOS, and activation of TRAIL and Fas-FasL apoptotic cascades.\",\n      \"method\": \"ELISA for IFN-β secretion, IRF-1/IRF-2 expression analysis, TRAIL/FasL measurement, apoptosis assays in melanoma cell lines\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, correlative mechanistic pathway with ELISA and expression analysis\",\n      \"pmids\": [\"18511292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Adenovirus-expressed MDA-7/IL-24 selectively increases the ratio of pro-apoptotic (BAX, BAK) to anti-apoptotic (BCL-2, BCL-XL) proteins in melanoma cells, causes G2/M cell cycle arrest, and leads to secretion of MDA-7 protein; normal melanocytes do not undergo apoptosis.\",\n      \"method\": \"Adenoviral gene transfer, western blot for BCL-2 family proteins, cell cycle analysis (flow cytometry), ELISA for secreted protein, normal vs. cancer cell comparison\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical readouts with normal/cancer selectivity demonstrated, foundational mechanistic paper\",\n      \"pmids\": [\"11850799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-17A binding to its receptor on Th17 cells activates NF-κB, which induces IL-24 expression in an autocrine loop; IL-24 in turn represses the Th17 cytokine program (GM-CSF, IL-17F) and in vivo treatment with IL-24 ameliorates autoimmune uveitis (EAU), while IL-24 silencing in Th17 cells enhances disease.\",\n      \"method\": \"In vitro mechanistic studies of NF-κB activation and IL-24 induction, IL-24 silencing in Th17 cells, in vivo EAU model with IL-24 treatment/silencing, human Th17 cell validation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro signaling mechanistic studies, in vivo gain/loss-of-function, validated in both mouse and human Th17 cells\",\n      \"pmids\": [\"32673565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In Th17 cells, IL-24 acts cell-intrinsically and independently of its cell-surface receptor to promote IL-10 secretion; IL-24 is recruited to the inner mitochondrial membrane where it interacts with NADH dehydrogenase subunit Grim19 (NDUFA13, complex I), and together Grim19 and IL-24 promote accumulation of STAT3 in the mitochondrial compartment, acting as a rheostat to blunt nuclear STAT3 activity and support robust IL-10 responses.\",\n      \"method\": \"Subcellular fractionation/localization of IL-24 to mitochondria, co-immunoprecipitation with Grim19, receptor-independent functional studies, mitochondrial STAT3 accumulation measurement, EAE model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP identifying novel intracellular binding partner, subcellular localization to mitochondria, receptor-independence established, functional in vivo validation\",\n      \"pmids\": [\"35819408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-24 synergizes with IL-4 to promote M2 macrophage polarization by suppressing IL-4-induced expression of SOCS1 and SOCS3, thereby enhancing STAT6/PPARγ signaling; IL-24 deficiency attenuates TGF-β1 production and M2 macrophage infiltration in bleomycin-induced pulmonary fibrosis.\",\n      \"method\": \"IL-24 knockout mice, SOCS1/SOCS3 expression analysis, STAT6/PPARγ signaling measurement, M2 macrophage quantification, BLM-induced fibrosis model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout model with mechanistic signaling analysis (SOCS1/3, STAT6/PPARγ) and disease model validation\",\n      \"pmids\": [\"33144678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-24 post-transcriptionally regulates CXCR4 mRNA by decreasing its half-life (>40%), thereby reducing CXCR4 protein and downstream signaling (pAKT, pmTOR, pPRAS40, HIF-1α), and inhibiting lung cancer cell migration and invasion; this is shown using doxycycline-inducible IL-24 expression, CXCR4 siRNA, and combination with CXCR4 antagonists.\",\n      \"method\": \"Doxycycline-inducible stable IL-24 expression, CXCR4 mRNA stability assay (half-life measurement), western blot for downstream targets, migration/invasion assays, CXCR4 siRNA, luciferase reporter\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible expression system, mRNA half-life measurement, siRNA and pharmacological validation, multiple downstream targets confirmed\",\n      \"pmids\": [\"25775124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MDA-7/IL-24 downregulates DICER (miRNA processing enzyme) in cancer cells but not normal cells, through canonical IL-20/IL-22 receptors; downregulation is ROS-dependent and mediated through the melanogenesis-associated transcription factor MITF. DICER downregulation reduces mature miR-221 (without affecting pri-miR-221) and contributes to cancer cell death; DICER overexpression rescues cells from MDA-7/IL-24-induced death.\",\n      \"method\": \"Gain/loss-of-function for DICER, MITF, and receptor manipulation; ROS measurement; northern/qPCR for miRNA biogenesis intermediates; stable DICER-overexpressing cell lines; in vivo xenograft with stable DICER cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic gain/loss-of-function experiments, receptor dependence established, ROS mechanistic link, in vivo validation\",\n      \"pmids\": [\"30842276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pharmacological inhibition of Mcl-1 with Sabutoclax (BI-97C1) sensitizes prostate cancer cells to MDA-7/IL-24-induced apoptosis; the combination causes autophagy that facilitates NOXA- and Bim-induced, Bak/Bax-mediated mitochondrial apoptosis; ABT-737 (which does not inhibit Mcl-1) does not sensitize cells, confirming Mcl-1 specificity.\",\n      \"method\": \"Pharmacological Mcl-1 inhibition, autophagy assay, NOXA/Bim/Bak/Bax assessment, xenograft and transgenic mouse models (Hi-myc), TUNEL/Ki-67 staining\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific Mcl-1 inhibitor vs. negative control (ABT-737), multiple in vivo models, apoptosis pathway dissection\",\n      \"pmids\": [\"21555592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZBTB7A transcriptionally represses LINC00473 by directly binding its promoter; LINC00473 interacts with transcription factor C/EBPβ, facilitating C/EBPβ binding to the IL24 promoter and promoting IL24 transcription. Loss of ZBTB7A reduces IL24 expression and increases cisplatin resistance in osteosarcoma.\",\n      \"method\": \"ChIP assay (ZBTB7A binding to LINC00473 promoter), RNA-protein interaction (LINC00473-C/EBPβ), C/EBPβ ChIP at IL24 promoter, loss/gain-of-function experiments\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP data for transcriptional regulation and RNA-protein interaction identifying the pathway, single lab\",\n      \"pmids\": [\"28942243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IL-24 inhibits TGFα-induced proliferation and migration of normal human epidermal keratinocytes (NHEKs) in vitro; IL-24 is expressed in keratinocytes during wound repair with maximum expression at days 2-6 post-wounding, induced by TGFα, TGFβ, IFNγ, and IFNβ.\",\n      \"method\": \"Immunohistochemistry of wound tissues, in vitro wound repair assay, migration assay, cytokine stimulation, western blot\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional migration/proliferation assays with cytokine induction data, single lab\",\n      \"pmids\": [\"20545760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-24 produced by mast cells (induced by T cell-derived microvesicles) activates keratinocyte STAT3 phosphorylation in vitro, establishing a functional signaling link between MC-derived IL-24 and keratinocyte activation.\",\n      \"method\": \"Co-culture of mast cells with microvesicles, ELISA for IL-24 protein, STAT3 phosphorylation assay in keratinocytes treated with MC-conditioned medium, immunohistochemistry of psoriatic lesions\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — in vitro functional assay (STAT3 phosphorylation) with conditioned medium approach, single lab\",\n      \"pmids\": [\"23768573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IL-24 induces apoptosis of IL-2-activated (cycling) CLL B cells through dephosphorylation of STAT3 (via activation of tyrosine phosphatase PTP1B) and concomitant stabilization and phosphorylation of p53; blocking phospho-STAT3 (a transcriptional repressor of p53) relieves repression of p53, which then drives apoptosis via caspase pathway.\",\n      \"method\": \"Sequential cytokine treatment (IL-2 then IL-24), phospho-STAT3 western blot, pervanadate (phosphatase inhibitor) reversal, p53 transcription/protein/phosphorylation assay, pifithrin-α (p53 inhibitor) rescue, caspase inhibitor rescue\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological rescue with multiple inhibitors and STAT3/p53 mechanistic pathway validated, single lab\",\n      \"pmids\": [\"18941194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-19, IL-20, and IL-24 signal through two heterodimeric receptor complexes: IL-20R1/IL-20R2 and IL-22R1/IL-20R2; both complexes are expressed on keratinocytes (IL-22R1 at 10-fold higher levels than IL-20R1), while immune cells lack these receptor chains and do not activate STAT molecules in response to these cytokines. IFN-γ further increases IL-22R1 and decreases IL-20R1 expression on keratinocytes.\",\n      \"method\": \"Quantitative receptor expression analysis (qPCR), STAT activation assay in immune cells and keratinocytes, cytokine stimulation experiments\",\n      \"journal\": \"Experimental dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic receptor expression and STAT activation analysis across multiple cell types, single lab\",\n      \"pmids\": [\"17083366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The mouse ortholog of IL-24 (FISP, IL-4-induced secreted protein) is selectively expressed and secreted by Th2 cells; its expression requires two signals: TCR signaling involving protein kinase C activation and STAT6-dependent IL-4R signaling.\",\n      \"method\": \"Th1/Th2 differentiation assays, pharmacological inhibition of PKC, IL-4R blocking, STAT6 requirement analysis, protein secretion assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined dual signaling requirement for expression with pharmacological dissection, foundational for Th2 biology of IL-24 ortholog\",\n      \"pmids\": [\"11342597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL-24 promotes epithelial-mesenchymal transition (EMT) in bronchial epithelial cells via STAT3 and ERK1/2 signaling pathways (upregulating vimentin and α-SMA, downregulating E-cadherin); IL-37 reverses IL-24-induced EMT by blocking ERK1/2 and STAT3, and in vivo IL-24 silencing or IL-37 treatment reverses EMT biomarker expression in an HDM-induced asthma model.\",\n      \"method\": \"BEAS-2B cell stimulation with IL-24, EMT biomarker (E-cadherin, vimentin, α-SMA) assay, wound healing/Transwell migration, STAT3/ERK1/2 phosphorylation assay, siRNA-IL-24 in vivo in murine asthma model\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro signaling pathway identification plus in vivo siRNA validation, single lab\",\n      \"pmids\": [\"36100847\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-24 (MDA-7/IL-24) is a secreted IL-10-family cytokine that signals canonically through IL-20R1/IL-20R2 and IL-22R1/IL-20R2 heterodimeric receptors to activate JAK/STAT pathways in epithelial/stromal target cells, but in cancer cells induces receptor-dependent or intracellular ER stress (through BiP/GRP78 interaction, PERK activation, ceramide generation via de novo and sphingomyelinase pathways, and ROS production) leading to translational suppression of Mcl-1, Bak oligomerization, p38 MAPK-driven GADD/SARI induction, and cancer-selective apoptosis or toxic autophagy; additionally, secreted MDA-7/IL-24 exerts antiangiogenic effects via the IL-22 receptor, drives an autocrine mRNA stabilization loop via p38 MAPK-mediated 3' UTR stabilization, downregulates DICER through an ROS/MITF axis, and in Th17 cells acts non-canonically by localizing to the inner mitochondrial membrane where it interacts with Grim19/NDUFA13 to promote mitochondrial STAT3 accumulation and IL-10 production, limiting immunopathology.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL-24 (MDA-7) is an IL-10-family cytokine with dual functionality: it acts as a canonical secreted ligand through IL-20R1/IL-20R2 and IL-22R1/IL-20R2 receptor complexes to activate JAK/STAT signaling in epithelial and stromal cells, and it drives cancer-selective apoptosis and toxic autophagy through receptor-independent intracellular mechanisms involving ER stress, ceramide generation, and ROS production [PMID:12811827, PMID:19937735, PMID:20103619]. In cancer cells, MDA-7/IL-24 binds the ER chaperone BiP/GRP78 and activates PERK, triggering ceramide elevation via de novo synthesis and acid sphingomyelinase, PP2A-mediated BCL-2 dephosphorylation, translational suppression of Mcl-1 with consequent Bak oligomerization, and p38 MAPK-dependent induction of GADD genes and SARI [PMID:16912197, PMID:20501829, PMID:24282278, PMID:19417161]. Secreted IL-24 sustains its own expression through a p38 MAPK-dependent autocrine mRNA stabilization loop acting on the 3′ UTR, inhibits angiogenesis via the IL-22 receptor, downregulates DICER through an ROS/MITF axis, and suppresses tumor cell migration by destabilizing CXCR4 mRNA and inhibiting PI3K/Akt/FAK signaling [PMID:18599461, PMID:20072629, PMID:12941841, PMID:30842276, PMID:25775124]. In Th17 cells, IL-24 functions non-canonically by localizing to the inner mitochondrial membrane where it interacts with NDUFA13 (Grim19) to promote mitochondrial STAT3 accumulation, blunting nuclear STAT3 activity and supporting IL-10 production to limit immunopathology [PMID:35819408, PMID:32673565].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that the mouse IL-24 ortholog (FISP) is a Th2-selective secreted cytokine requiring dual TCR/PKC and STAT6/IL-4R signals resolved the immune-cell context of IL-24 expression before its receptor biology was known.\",\n      \"evidence\": \"Th1/Th2 differentiation with pharmacological dissection of PKC and STAT6 requirements in mouse T cells\",\n      \"pmids\": [\"11342597\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; not replicated with genetic knockouts of PKC isoforms\", \"Th2-selectivity was mouse-specific and later complicated by Th17 expression in humans\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that adenoviral MDA-7/IL-24 selectively shifts the BAX/BCL-2 ratio and induces G2/M arrest in melanoma but not normal melanocytes established the cancer-selective killing paradigm that dominated subsequent mechanistic dissection.\",\n      \"evidence\": \"Adenoviral expression in paired normal/cancer melanocyte lines with BCL-2 family protein and cell-cycle analysis\",\n      \"pmids\": [\"11850799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of cancer selectivity not identified\", \"Overexpression system; endogenous IL-24 levels not assessed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying IL-20R1/IL-20R2 and IL-22R1/IL-20R2 as IL-24 receptors that activate JAK/STAT, while showing cancer-cell killing is JAK/STAT-independent and partially p38 MAPK-dependent, bifurcated the field into canonical signaling versus intracellular death pathways.\",\n      \"evidence\": \"JAK inhibitors, STAT/JAK-deficient cell lines, p38 MAPK inhibitor, and receptor expression analysis across cancer lines\",\n      \"pmids\": [\"12811827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the intracellular death trigger remained unknown\", \"p38 MAPK inhibitor only partially blocked killing, indicating additional pathways\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Secreted MDA-7/IL-24 was shown to inhibit VEGF- and bFGF-driven angiogenesis through the IL-22 receptor, establishing a paracrine antitumor mechanism distinct from direct cancer-cell killing.\",\n      \"evidence\": \"IL-22R blocking antibody, endothelial differentiation/migration assays, in vivo Matrigel plug and xenograft models\",\n      \"pmids\": [\"12941841\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream endothelial signaling pathway not delineated\", \"Contribution of antiangiogenesis versus direct killing to in vivo efficacy unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapping the death-receptor arm showed MDA-7/IL-24 activates c-Jun/ATF2 to transcriptionally induce FasL and Fas, engaging FADD/caspase-8-mediated extrinsic apoptosis in ovarian cancer cells.\",\n      \"evidence\": \"FasL promoter-reporter, Fas siRNA, FasL blocking antibody, caspase-8 pathway analysis\",\n      \"pmids\": [\"15833826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Fas/FasL arm operates in non-ovarian cancers was not tested\", \"Upstream trigger linking MDA-7/IL-24 to c-Jun/ATF2 activation not identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying BiP/GRP78 as a direct MDA-7/IL-24 binding partner via its C and F helices, with consequent p38 MAPK activation and GADD induction, provided the first molecular explanation for the intracellular ER-stress death pathway.\",\n      \"evidence\": \"Deletion/point mutagenesis of MDA-7/IL-24, co-immunoprecipitation with BiP/GRP78, subcellular ER localization\",\n      \"pmids\": [\"16912197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of BiP interaction not resolved at atomic level\", \"Whether BiP binding is necessary or sufficient for cancer selectivity not tested with BiP knockdown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The discovery that secreted MDA-7/IL-24 autocrine-induces its own mRNA through posttranscriptional stabilization (not transcription), sustaining ER stress and ROS, explained the bystander killing phenomenon in untransduced neighboring cancer cells.\",\n      \"evidence\": \"Promoter activity ruling out transcriptional activation, mRNA stability assays, protein synthesis inhibitor, ER stress and ROS markers\",\n      \"pmids\": [\"18599461\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RNA-binding protein mediating stabilization not identified\", \"Whether autocrine loop operates through the same IL-20R/IL-22R receptors not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"PERK was established as a required upstream kinase for MDA-7/IL-24-induced autophagy in glioma, linking ER stress to LC3-positive autophagic vacuole formation and subsequent BAX/JNK-mediated mitochondrial apoptosis.\",\n      \"evidence\": \"PERK−/− cells, ATG5/Beclin-1 siRNA, autophagy inhibitor 3-MA, recombinant GST-MDA-7 treatment\",\n      \"pmids\": [\"18299661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PERK activation is direct or secondary to BiP sequestration not resolved\", \"Cell-type generality of autophagy-to-apoptosis conversion unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Ceramide was identified as a critical second messenger: MDA-7/IL-24 elevates C16/C24/C24:1 ceramides selectively in cancer cells via de novo synthesis and acid sphingomyelinase, activating PP2A to dephosphorylate BCL-2, while PERK was placed upstream of ceramide generation and ROS production.\",\n      \"evidence\": \"Ceramide mass spectrometry, myriocin/fumonisin B1 inhibitors, ASMase siRNA, PERK−/− cells, Ca²⁺ and ROS measurement\",\n      \"pmids\": [\"19937735\", \"20103619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ceramide elevation is the primary cancer-selectivity determinant or a downstream amplifier is unclear\", \"Role of specific ceramide synthases beyond CerS6 not fully explored\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Translational suppression of Mcl-1 was identified as the key effector of ER stress-mediated apoptosis: MDA-7/IL-24-induced ER stress inhibits Mcl-1 translation, releasing Bak for oligomerization and mitochondrial apoptosis.\",\n      \"evidence\": \"Forced Mcl-1 expression rescue, Mcl-1 siRNA/knockout sensitization, Mcl-1–Bak co-immunoprecipitation showing dissociation\",\n      \"pmids\": [\"20501829\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Mcl-1 translational suppression is eIF2α-phosphorylation-dependent was inferred but not directly tested with eIF2α mutants\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"p38 MAPK was shown to stabilize IL-24 mRNA via its 3′ UTR, providing the molecular basis for the autocrine amplification loop and positioning p38 MAPK as both a downstream effector and a feed-forward stabilizer of IL-24 expression.\",\n      \"evidence\": \"Tet-off 3′ UTR reporter, p38 MAPK inhibitor SB202190, constitutively active MKK6\",\n      \"pmids\": [\"20072629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific RNA-binding protein(s) that p38 MAPK regulates to stabilize IL-24 mRNA remain unidentified\", \"Whether this loop operates in immune cells in addition to cancer cells is unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Ceramide-dependent CD95 (Fas) clustering at the plasma membrane was linked to MDA-7/IL-24 action in renal carcinoma, unifying the ceramide and death-receptor pathways: ASMase/CerS6-generated ceramide causes CD95 aggregation and procaspase-8 recruitment, upstream of PERK-dependent JNK/p38 signaling.\",\n      \"evidence\": \"CD95 clustering assay, ASMase/CerS6 siRNA, PERK dominant-negative and knockout, co-IP of CD95 with procaspase-8\",\n      \"pmids\": [\"19417161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD95 clustering is a general feature across cancer types or renal-carcinoma-specific\", \"Temporal ordering of ceramide versus PERK activation not fully resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"SARI (suppressor of AP-1) was identified as a necessary downstream effector of MDA-7/IL-24's antitumor activity, induced through receptor-mediated p38 MAPK signaling, connecting the extracellular signaling arm to intracellular tumor suppression.\",\n      \"evidence\": \"SARI antisense abolishing MDA-7/IL-24 killing, p38 MAPK inhibitor, recombinant His-MDA-7 acting through IL-20R/IL-22R receptors\",\n      \"pmids\": [\"24282278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SARI's direct transcriptional targets mediating apoptosis not defined\", \"Whether SARI is required in all cancer types not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"IL-24 was shown to post-transcriptionally destabilize CXCR4 mRNA, reducing its half-life by >40%, thereby suppressing AKT/mTOR/HIF-1α signaling and cancer cell migration — extending IL-24's anti-invasion mechanism beyond FAK/MMP suppression.\",\n      \"evidence\": \"Doxycycline-inducible IL-24, CXCR4 mRNA half-life measurement, CXCR4 siRNA, migration/invasion assays\",\n      \"pmids\": [\"25775124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The RNA-destabilizing mechanism (e.g., specific RBP or miRNA involved) not identified\", \"Whether CXCR4 mRNA destabilization occurs in non-lung cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"MDA-7/IL-24 was found to downregulate DICER through receptor-dependent ROS production and MITF suppression, cancer-selectively impairing miRNA biogenesis (e.g., reducing mature miR-221); DICER overexpression rescued cancer cells, establishing a novel effector arm.\",\n      \"evidence\": \"DICER gain/loss-of-function, MITF manipulation, ROS measurement, northern blot for miRNA intermediates, in vivo xenograft rescue\",\n      \"pmids\": [\"30842276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which DICER-dependent miRNAs beyond miR-221 are functionally important not mapped\", \"How MITF downregulation specifically targets DICER transcription not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"In Th17 cells, IL-17A-induced NF-κB was shown to drive autocrine IL-24 expression, which in turn represses the pathogenic Th17 program (GM-CSF, IL-17F) and ameliorates autoimmune uveitis, establishing IL-24 as an intrinsic negative-feedback cytokine in Th17 biology.\",\n      \"evidence\": \"NF-κB signaling dissection, IL-24 silencing in Th17 cells, in vivo EAU model with IL-24 treatment/silencing, human Th17 validation\",\n      \"pmids\": [\"32673565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-24 represses GM-CSF/IL-17F transcriptionally or post-transcriptionally not resolved\", \"Receptor dependence versus intracellular action in Th17 regulation not distinguished in this study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"IL-24 was shown to synergize with IL-4 to promote M2 macrophage polarization by suppressing SOCS1/SOCS3, enhancing STAT6/PPARγ, and IL-24 deficiency attenuated pulmonary fibrosis, revealing a pro-fibrotic immunomodulatory role distinct from its antitumor function.\",\n      \"evidence\": \"IL-24 knockout mice, SOCS1/3 and STAT6/PPARγ signaling analysis, bleomycin-induced fibrosis model\",\n      \"pmids\": [\"33144678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-24 acts directly on macrophages or indirectly through other cell types not fully resolved\", \"Receptor complex mediating IL-24's effect on macrophages not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The discovery that IL-24 localizes to the inner mitochondrial membrane and interacts with NDUFA13/Grim19 to promote mitochondrial STAT3 accumulation — independently of its cell-surface receptors — established a non-canonical cell-intrinsic mechanism by which IL-24 supports IL-10 production in Th17 cells and limits autoimmune pathology.\",\n      \"evidence\": \"Subcellular fractionation, co-immunoprecipitation with Grim19, receptor-independent functional assays, mitochondrial STAT3 measurement, EAE model\",\n      \"pmids\": [\"35819408\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IL-24 is imported into the inner mitochondrial membrane is unknown\", \"Whether mitochondrial IL-24 function extends to other immune or non-immune cell types not tested\", \"Structural basis of IL-24–Grim19 interaction not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular basis of cancer selectivity — why intracellular MDA-7/IL-24 triggers ER stress and apoptosis in tumor cells but not normal cells — remains mechanistically unresolved despite extensive downstream pathway characterization.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cancer-cell-specific factor or threshold mechanism identified\", \"How mitochondrial and ER-stress functions relate to each other in immune cells is unexplored\", \"No structural model of IL-24 in complex with BiP, Grim19, or receptors exists\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 12, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [19, 21, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2, 4, 6]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 4, 18, 30]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3, 5, 6, 7, 10, 11, 18, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 12, 19, 21, 28, 31]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 20, 21]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [7, 10, 13, 24]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [15, 16, 22, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HSPA5\",\n      \"NDUFA13\",\n      \"IL20RB\",\n      \"IL20RA\",\n      \"IL22RA1\",\n      \"BECN1\",\n      \"CLU\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}